Asset Details
Do you wish to reserve the book?
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
Do you wish to request the book?
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
2012
Overview
Summary
Treatment of metastatic renal cell carcinoma (mRCC) has evolved rapidly over the last two decades as major pathways involved in pathogenesis have been elucidated. These include the vascular endothelial growth factor (VEGF) axis and mammalian target of rapamycin (mTOR). Therapies targeting the VEGF pathway include bevacizumab, sorafenib, sunitinib, pazopanib, and axitinib, whereas temsirolimus and everolimus inhibit the mTOR pathway. All of these novel therapies—VEGF and mTOR inhibitors—are associated with a variety of unique toxicities, some of which may necessitate expert medical management, treatment interruption, or dose reduction. Common adverse events with newer drugs include hypertension, skin reactions, gastrointestinal disturbances, thyroid dysfunction, and fatigue. Skilled management of these toxicities is vital to ensure optimal therapeutic dosing and maximize patient outcomes, including improved survival and quality of life. This review describes and compares the toxicity profiles of novel molecularly targeted agents used in the treatment of mRCC and presents guidance on how best to prevent and manage treatment-related toxicities. Particular attention is given to axitinib, the newest agent to enter the armamentarium. Axitinib is a second-generation receptor tyrosine kinase inhibitor with potent VEGF receptor inhibition that provides durable responses and superior progression-free survival in advanced RCC compared with sorafenib.
Publisher
Springer US
Subject
Angiogenesis Inhibitors - adverse effects
/ Angiogenesis Inhibitors - therapeutic use
/ Carcinoma, Renal Cell - blood supply
/ Carcinoma, Renal Cell - drug therapy
/ Carcinoma, Renal Cell - metabolism
/ Humans
/ Kidney Neoplasms - blood supply
/ Kidney Neoplasms - drug therapy
/ Kidney Neoplasms - metabolism
/ Medicine
/ Molecular Targeted Therapy - methods
/ Neovascularization, Pathologic - drug therapy
/ Oncology
/ Review
/ TOR Serine-Threonine Kinases - antagonists & inhibitors
/ TOR Serine-Threonine Kinases - metabolism
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
